Dr. Arnold Caplan

Chief Scientific Officer at OrthoCyte Corporation, a subsidiary of BioTime, Inc. since June 2010. Dr. Caplan is a Professor of Biology & General Medical Sciences (Oncology) and Director of Cellular and Molecular Basis for Aging Training Program of Case Western Reserve University in Cleveland, Ohio. and serves as its Director of Skeletal Research Center. Dr. Caplan co-founded Cell Targeting Inc. He served as President of Skeletech, Inc. and its founder. He served as Chief Scientific Officer and founder of Osiris Therapeutics, Inc. He serves as Director of BioMetic Pharmaceuticals, Inc. He has been a Director of Biomimetics Pharmaceuticals, Inc. since March 2001. Dr. Caplan serves as a Member of Scientific Advisory Board at IsoTis, Inc. and SanBio Inc. He serves as a Member of Scientific Advisory Board of IsoTis S.A. He serves as member of Orthopedic Scientific Advisory Board at BioMimetic Therapeutics. He served as a Director of Carbylan Biosurgery, Inc. and BioMimetic Therapeutics Inc. from March 2001 to September 2006. He served as a Director of Osiris Therapeutics, Inc. Dr. Caplan has lectured and published extensively within the fields of cellular and molecular, developmental and bone biology and is recognized as one of the foremost authorities on tissue regeneration. He is the recipient of several honors and awards from the orthopedic research community. Dr. Caplan holds his Ph.D. from Johns Hopkins University Medical School and a B.S in chemistry from the Illinois Institute of Technology.

Luciana Benedetti

• Médico Veterinaria egresada de la Universidad de El Salvador en el 2003.
• Trabajó 6 años en el Servicio de Medicina Hiperbárica Equina y Escuela Argentina de Herradores.
• Dirige su establecimiento privado de Rehabilitación y Entrenamiento Equino “El Alpino” desde 2004.
• En 2006 funda y dirige la Unidad de Medicina Regenerativa Veterinaria del Instituto de Ciencias Básicas y Medicina experimental- Hospital Italiano de Buenos Aires, siendo pionera en terapias celulares veterinarias en Argentina.
• Ha realizado disertaciones y publicaciones internacionalmente, recibiendo distinciones y becas por parte del Ministerio de Ciencia y Tecnología Argentina.

Dr. Oren Levy

Dr. Oren Levy received his B.Sc. degree in Biology from Ben Gurion University (BGU), Israel. He carried out his M.Sc. and PhD research in BGU, focusing on key signaling pathways and their involvement in human mesenchymal stem cells (MSC) biology. Dr. Levy then joined the lab of Dr. Jeffrey Karp at Harvard Medical School/Brigham and Women’s Hospital as a postdoctoral research fellow.  As Instructor of Medicine at Harvard Medical School, Oren’s research in recent years focused on developing cutting-edge bioengineering strategies to advance cell-based therapies by enhancing the control over cell fate following transplantation. As a staff scientist at the Wyss, Oren now focuses on harnessing organ-on-chip models to better understand disease mechanisms and develop novel therapeutics.

Barbara Krutchkoff, PhD 

A consultant for physicians and biomedical start up companies in regenerative and cellular medicine and Chief of Scientific Affairs for Lipogems US. She is Executive Director of the 501c3 Institute of Regenerative and Cellular Medicine, which provides support for translational research and validation of regenerative therapies. Her A3Cell consultancy helps practitioners and biotech entrepreneurs navigate the regulatory pathway, as well as design and manage clinical studies. Barbara has worked tirelessly throughout her 25+ year career to engage with university and industry leaders to help bring regenerative medicine safely to patients. Her educational background includes physics and computer science at the University of Florida, biomedical engineering graduate studies at Virginia Tech, a PhD in behavioral psychology, a Doctorate in integrative medicine, and a Stem Cell Fellowship at UCLA. She is a board certified Diplomat and Fellow of the AARBM.

Dr. Bruce Werber

Currently Dr. Werber is the Chief Operating officer of BioTech Products, Services and Research a public company. From 2011 to 2016, Dr. Werber served as a consultant of medical and surgical industries of Cuboid Associates. From 1981 to 2014, Dr. Werber practiced as a Board Certified reconstructive foot and ankle surgeon in Rhode Island and then in Arizona, the CEO of several medical practices. In 2012, Dr. Werber founded and, from 2012 to 2015, served as the President of Amnio Technology LLC, creating the company as well as developing the processing and clinical science related to utilizing placental tissue in orthopedic medicine. Prior to founding Amnio Technology, Dr. Werber wrote and published two peer reviewed papers relating to using placental tissue in the treatment of diabetic wounds, plantar fasciosis and Achilles tendinosis. Dr. Werber has spoken and lectured on this topic extensively around the United States and internationally. Dr. Werber has completed surgical fellowships in 2003 Athens Institute for Orthopedics in Athens Greece, 2002/04 at the Ilizarov Institute in Kurgan Russia, and in 1989 Hadassah Hospital Jerusalem Israel. Developing expertise in diabetic foot conditions most notably reconstruction of the Charcot Foot with external fixation.

Dr. Werber has submitted eight patent applications in the area of placental tissue, seven of which are still pending and one has been granted.  Dr. Werber served as the Present of the American College of Foot and Ankle surgeons from 2003 to 2004. He has been a leader in the field of foot and ankle surgery, introducing new successful technologies to improve patient outcomes. His extensive business experience includes the development of the northeast franchisee of Discovery Zone, in addition to founding and managing successful medical practices in Rhode Island and Arizona.  Dr. Werber earned his DPM (Doctor of Podiatric Medicine) in 1980 from the California College of Podiatric Medicine in San Francisco, CA and a B.S. in Biology-Physics in 1976 from Syracuse University in Syracuse, NY.

David Angeloni, PhD

David Angeloni is Chief Scientist of Millennium Medical Technologies and Lead Scientist for AQ Skin Solutions. His career started as a clinical scientist at U.S. Labs in Irvine, California, where he played a key role in starting its genetics division and which eventually lead to the company being acquired by Laboratory Corporation of America in 2005 for $162 million. Since then, he has been either employed by or consulted for several biotech companies, including; ChromaVision Medical Systems (now Clarient), Alliance Medical Products (a Siegfried Company), and MP Biomedicals, LLC. David has also been a part of creating several patents held by Vysis (now owned by Abbot Laboratories) and working in the field of clinical diagnostics at Applied Imaging (later owned by Genetix before its acquisition by Molecular Devices, Inc.). He has extensive knowledge in the field of regenerative medicine, having presented and published 12 peer reviewed abstracts with colleagues regarding the clinical use of growth factors or adipose derived stem cells over the past 5 years. He holds a B.S. in Biology and a M.S. in Biological Sciences with an emphasis on microbiology, molecular genetics, and pathology, and holds a Ph.D. “all but dissertation” status in academia which he plans to complete soon.

Gregorio Chazenbalk, PhD

As a basic scientist with more than 30 years of experience in molecular and cellular biology, Dr Chazenbalk has demonstrated substantial leadership experience in directing successful and productive research. His efforts has produced a body of work in the fields of molecular endocrinology, immunology, and cell biology resulting in more than 100 publications in prestigious journals such as Science, Proceedings of the National Academy of Sciences of the United States of America, Journal of Clinical Investigation, Journal of Biological Chemistry, Journal Clinical Endocrinology and Metabolism, and others. Early in his career, Dr Chazenbalk was awarded multiple scholarships from the Argentine Foundation of Endocrinology, the National Research Council of Argentina and the Argentine Endocrinology Foundation. After working for more than 20 years in thyroid research at the VA Hospital of San Francisco, the University of California, San Francisco (UCSF) and in the Thyroid Autoimmunity Disease Unit at Cedars Sinai Medical Center, Los Angeles, Dr Chazenbalk has been recognized internationally as an expert in thyroid regulation and autoimmunity. During that period, Dr Chazenbalk cloned the entire repertoire of human thyroid peroxidase autoantibodies which play a critical role in Hashimoto’s thyroiditis and conducted critical studies on the structure-function of the human thyrotropin receptor (TSHR), primary antigen of Graves’ disease. In addition, Dr Chazenbalk has pioneered discoveries on the cleavage site of the human thyrotropin receptor which has wide-ranging implications for the understanding of the pathophysiology of Graves’ Disease at both the molecular and cellular levels. His work in this field led him to successfully engineer the human thyrotropin receptor A subunit. The availability of this protein ignited further studies illuminating its crucial role in the initiation and/or amplification of the autoimmune response in Graves disease. Dr Chazenbalk was honored in 2001 to receive the prestigious award “Best Thyroid Scientist” from the Latin American Thyroid Association for my work in this field. In 2006, Dr Chazenbalk joined the Department of Obstetrics and Gynecology at Cedars-Sinai Medical Center as a scientist and as a member of the faculty of the Departments of Medicine and Obstetrics and Gynecology at UCLA. Since that time, Dr Chazenbalk has examined the role of inflammation in insulin resistance in adipose tissue of patients with Polycystic Ovary Syndrome (PCOS). Dr Chazenbalk was the first scientist to demonstrate that the accumulation of preadipocytes can be accelerated in vitro via cross-talk between adipocytes and resident macrophages and adipose stem cells, which can generate new adipocytes. This phenomenon may lead to the development of novel methods of tissue regeneration and reconstructive medicine, as well as in 2013, Dr Chazenbalk discovered a novel population of stem cells with pluripotent characteristics isolated from human adipose tissue. Despite their pluripotency, these stem cells do not produce teratomas in vivo, offering new avenues to treat many disorders (stroke, heart attack, diabetes, neurodegenerative and immune disorders, etc). This discovery has made a significant impact in the fields of regenerative medicine and cell therapy and has been recognized in the national and international media. It has also led to a patent application entitled “Pluripotent Human Adipose Adult Stem Cells: Isolation, Characterization and Clinical Implications.” Dr Chazenbalk received in 2014 an award from the Japanese Society of Science for his work in this field and to be invited to serve as the Editor of a scientific book entitled, “Muse Cells: A New Era of Pluripotent Stem Cells”, which is scheduled for publication by Springer in September 2015.

Graham Parker, PhD

• Profesor del Departmento de Pediatría de Wayne State University School of Medicine Detroit, MI.
• Ganador de multiples Honores y reconocimientos internacionales. Uno de los pioneros en el campo de las Células Madre publicando desde el 2003.
• Más de 721 citations.
• Más de 50 publicaciones en el campo de las células madre.
• Ha presentado en más de 50 eventos de Medicina Regenerativa internacionalmente.

Ignacio Dallo

• Médico Traumatólogo graduado en la Universidad Nacional de Rosario, Argentina, en el año 2002 con Homologación de su título en España y Unión Europea.
• Especialista Certificado por la Asociación Argentina de Ortopedia y Traumatología y cirujano acreditado por la Asociación Argentina de Artroscopia
• Fellowship de Artroscopia y Traumatología Deportiva en la Clínica Cemtro de Madrid (Centro certificado por la FIFA) donde trató a jugadores del Real Madrid y del Atlético de Madrid y obtuvo una experiencia significativa con el cultivo de condrocitos por lesiones cartílago articular.
• Visiting Fellows en Regenerative Sports Medicine en el Rush University Medical Center con el Dr. Brian Cole, Hospital for Special Surgery con el Dr. Scott Rodeo y Steadman  Philippon Research Institute con el Dr. Rober LaPrade
• Es Miembro de la Comisión directiva de la Asociación Argentina de Traumatología del Deporte.
• Ha realizado publicaciones científicas y disertaciones nacionales e internacionales.
• Es Pionero y referente en el campo de la Medicina Regenerativa en Ortopedia y Traumatología del Deporte

Natalia Luka

• Médico Veterinaria, especialista en Clínica de Pequeños Animales, con posgrado en Medicina Felina y talleres de Inmunología e Inmunooncología del 2012 al 2015
• Trabaja en Medicina Regenerativa Veterinaria desde el 2014 a la actualidad en la empresa Rscell en Argentina
• Desde el 2008 a la actualidad colabora en el Centro de Inmunología
  Veterinaria
• Experiencia en Manejo del dolor y enfermedad renal crónica manejadas

Dra. Priscilla Ortiz

Graduate in Medicine and Veterinary Surgery at the University San Francisco de Asís, Véritas, Costa Rica in 2011. That same year she completed a 5-month internship at the Pet Emergency Hospital in Orlando, Florida. During that internship, she became acquainted with Cell Therapy and since then, she has collaborated on the first canine treatments performed by Dr. Dan Evers.

As part of its training, in early 2012, she attends an intensive 6-week theoretical-practical training on the use of adipose tissue stem cells in animals with MediVet America, DeLand and Daytona, Florida. In 2013 she trains with the president of the Latin American Stem Cell Society. This training was theoretical and practical by the company Stemprocell, Santo Domingo, Dominican Republic. This training consisted of various protocols of application in aesthetics and pathologies of plasma rich in platelets and stem cells derived from adipose tissue and bone marrow in humans. In 2014, she participates in a Millenium Medical Workshop on regenerative medicine with stem cells derived from adipose tissue in humans, the workshop was held in Los Angeles, California.

As part of her continuous education process, she attends some of the most important events worldwide in this field such as the World Stem Cell Summit in the years 2012, 2013 and 2015, the Seminar of Veterinary Regenerative Medicine VitaStemcell in the 2013 in Santiago, Chile, the Third Annual Clinical and Surgical Translation of Stem Cells 2015 in San Diego, California, and the Harvard MSC Colloquium Road to Translation by the Harvard Stem Cell Institute in 2016 among others.